-DOCSTART- -X- O
Ebola -X- _ B-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
EBOV -X- _ I-Patient
) -X- _ I-Patient
, -X- _ O
a -X- _ O
member -X- _ O
of -X- _ O
the -X- _ O
family -X- _ O
Filoviridae -X- _ O
, -X- _ O
is -X- _ O
responsible -X- _ O
for -X- _ O
causing -X- _ O
Ebola -X- _ B-Patient
virus -X- _ I-Patient
disease -X- _ I-Patient
( -X- _ I-Patient
EVD -X- _ I-Patient
) -X- _ I-Patient
( -X- _ O
formerly -X- _ O
named -X- _ O
Ebola -X- _ B-Patient
hemorrhagic -X- _ I-Patient
fever -X- _ I-Patient
) -X- _ O
. -X- _ O
This -X- _ O
is -X- _ O
a -X- _ O
severe -X- _ O
, -X- _ O
often -X- _ O
fatal -X- _ O
illness -X- _ O
with -X- _ O
mortality -X- _ O
rates -X- _ O
varying -X- _ O
from -X- _ O
50 -X- _ O
to -X- _ O
90 -X- _ O
% -X- _ O
in -X- _ O
humans. -X- _ O
Although -X- _ O
the -X- _ O
virus -X- _ O
and -X- _ O
associated -X- _ O
disease -X- _ O
has -X- _ O
been -X- _ O
recognized -X- _ O
since -X- _ O
1976 -X- _ O
, -X- _ O
it -X- _ O
was -X- _ O
only -X- _ O
when -X- _ O
the -X- _ O
recent -X- _ O
outbreak -X- _ O
of -X- _ O
EBOV -X- _ O
in -X- _ O
2014â€“2016 -X- _ O
highlighted -X- _ O
the -X- _ O
danger -X- _ O
and -X- _ O
global -X- _ O
impact -X- _ O
of -X- _ O
this -X- _ O
virus -X- _ O
, -X- _ O
necessitating -X- _ O
the -X- _ O
need -X- _ O
for -X- _ O
coming -X- _ O
up -X- _ O
with -X- _ O
the -X- _ O
effective -X- _ O
vaccines -X- _ O
and -X- _ O
drugs -X- _ O
to -X- _ O
counter -X- _ O
its -X- _ O
pandemic -X- _ O
threat. -X- _ O
Albeit -X- _ O
no -X- _ O
commercial -X- _ O
vaccine -X- _ O
is -X- _ O
available -X- _ O
so -X- _ O
far -X- _ O
against -X- _ O
EBOV -X- _ O
, -X- _ O
a -X- _ O
few -X- _ O
vaccine -X- _ O
candidates -X- _ O
are -X- _ O
under -X- _ O
evaluation -X- _ O
and -X- _ O
clinical -X- _ O
trials -X- _ O
to -X- _ O
assess -X- _ O
their -X- _ O
prophylactic -X- _ O
efficacy. -X- _ O
These -X- _ O
include -X- _ O
recombinant -X- _ B-Intervention
viral -X- _ I-Intervention
vector -X- _ I-Intervention
( -X- _ I-Intervention
recombinant -X- _ I-Intervention
vesicular -X- _ I-Intervention
stomatitis -X- _ I-Intervention
virus -X- _ I-Intervention
vector -X- _ I-Intervention
, -X- _ I-Intervention
chimpanzee -X- _ I-Intervention
adenovirus -X- _ I-Intervention
type -X- _ I-Intervention
3-vector -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
modified -X- _ I-Intervention
vaccinia -X- _ I-Intervention
Ankara -X- _ I-Intervention
virus -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
Ebola -X- _ B-Intervention
virus-like -X- _ I-Intervention
particles -X- _ I-Intervention
, -X- _ O
virus-like -X- _ B-Intervention
replicon -X- _ I-Intervention
particles -X- _ I-Intervention
, -X- _ O
DNA -X- _ B-Intervention
, -X- _ O
and -X- _ O
plant-based -X- _ B-Intervention
vaccines. -X- _ I-Intervention
Due -X- _ O
to -X- _ O
improvement -X- _ O
in -X- _ O
the -X- _ O
field -X- _ O
of -X- _ O
genomics -X- _ O
and -X- _ O
proteomics -X- _ O
, -X- _ O
epitope-targeted -X- _ O
vaccines -X- _ O
have -X- _ O
gained -X- _ O
top -X- _ O
priority. -X- _ O
Correspondingly -X- _ O
, -X- _ O
several -X- _ O
therapies -X- _ O
have -X- _ O
also -X- _ O
been -X- _ O
developed -X- _ O
, -X- _ O
including -X- _ O
immunoglobulins -X- _ B-Intervention
against -X- _ O
specific -X- _ O
viral -X- _ O
structures -X- _ O
small -X- _ O
cell-penetrating -X- _ O
antibody -X- _ O
fragments -X- _ O
that -X- _ O
target -X- _ O
intracellular -X- _ O
EBOV -X- _ O
proteins. -X- _ O
Small -X- _ B-Intervention
interfering -X- _ I-Intervention
RNAs -X- _ I-Intervention
and -X- _ I-Intervention
oligomer-mediated -X- _ I-Intervention
inhibition -X- _ I-Intervention
have -X- _ O
also -X- _ O
been -X- _ O
verified -X- _ O
for -X- _ O
EVD -X- _ O
treatment. -X- _ O
Other -X- _ O
treatment -X- _ O
options -X- _ O
include -X- _ O
viral -X- _ B-Intervention
entry -X- _ I-Intervention
inhibitors -X- _ I-Intervention
, -X- _ I-Intervention
transfusion -X- _ I-Intervention
of -X- _ I-Intervention
convalescent -X- _ I-Intervention
blood -X- _ I-Intervention
/ -X- _ I-Intervention
serum -X- _ I-Intervention
, -X- _ I-Intervention
neutralizing -X- _ I-Intervention
antibodies -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
gene -X- _ I-Intervention
expression -X- _ I-Intervention
inhibitors. -X- _ I-Intervention
Repurposed -X- _ O
drugs -X- _ O
, -X- _ O
which -X- _ O
have -X- _ O
proven -X- _ O
safety -X- _ O
profiles -X- _ O
, -X- _ O
can -X- _ O
be -X- _ O
adapted -X- _ O
after -X- _ O
high-throughput -X- _ O
screening -X- _ O
for -X- _ O
efficacy -X- _ O
and -X- _ O
potency -X- _ O
for -X- _ O
EVD -X- _ O
treatment. -X- _ O
Herbal -X- _ O
and -X- _ O
other -X- _ O
natural -X- _ O
products -X- _ O
are -X- _ O
also -X- _ O
being -X- _ O
explored -X- _ O
for -X- _ O
EVD -X- _ O
treatment. -X- _ O
Further -X- _ O
studies -X- _ O
to -X- _ O
better -X- _ O
understand -X- _ O
the -X- _ O
pathogenesis -X- _ O
and -X- _ O
antigenic -X- _ O
structures -X- _ O
of -X- _ O
the -X- _ O
virus -X- _ O
can -X- _ O
help -X- _ O
in -X- _ O
developing -X- _ O
an -X- _ O
effective -X- _ O
vaccine -X- _ O
and -X- _ O
identifying -X- _ O
appropriate -X- _ O
antiviral -X- _ O
targets. -X- _ O
This -X- _ O
review -X- _ O
presents -X- _ O
the -X- _ O
recent -X- _ B-Outcome
advances -X- _ I-Outcome
in -X- _ I-Outcome
designing -X- _ I-Outcome
and -X- _ I-Outcome
developing -X- _ I-Outcome
vaccines -X- _ I-Outcome
, -X- _ I-Outcome
drugs -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
therapies -X- _ I-Outcome
to -X- _ I-Outcome
counter -X- _ I-Outcome
the -X- _ I-Outcome
EBOV -X- _ I-Outcome
threat -X- _ I-Outcome
. -X- _ O

